CN114088939A - 一种原发性胆汁性胆管炎诊断用分子标志物及其应用 - Google Patents
一种原发性胆汁性胆管炎诊断用分子标志物及其应用 Download PDFInfo
- Publication number
- CN114088939A CN114088939A CN202111375805.0A CN202111375805A CN114088939A CN 114088939 A CN114088939 A CN 114088939A CN 202111375805 A CN202111375805 A CN 202111375805A CN 114088939 A CN114088939 A CN 114088939A
- Authority
- CN
- China
- Prior art keywords
- sample
- pbc
- human
- antibody
- immunoglobulin receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 title claims abstract description 64
- 208000012654 Primary biliary cholangitis Diseases 0.000 title claims abstract description 64
- 238000003745 diagnosis Methods 0.000 title claims abstract description 24
- 239000003147 molecular marker Substances 0.000 title claims abstract description 11
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 56
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 56
- 102000005962 receptors Human genes 0.000 claims abstract description 51
- 108020003175 receptors Proteins 0.000 claims abstract description 51
- 210000002966 serum Anatomy 0.000 claims abstract description 28
- 229920000642 polymer Polymers 0.000 claims abstract description 19
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims description 16
- 238000005406 washing Methods 0.000 claims description 14
- 238000007789 sealing Methods 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 11
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 10
- 238000002965 ELISA Methods 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- 238000008157 ELISA kit Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 6
- 239000012089 stop solution Substances 0.000 claims description 6
- 239000011534 wash buffer Substances 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 238000012417 linear regression Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 12
- 210000000013 bile duct Anatomy 0.000 abstract description 9
- 230000006378 damage Effects 0.000 abstract description 6
- 230000008506 pathogenesis Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- 239000006180 TBST buffer Substances 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000005228 liver tissue Anatomy 0.000 description 7
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 7
- 206010008635 Cholestasis Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000002055 immunohistochemical effect Effects 0.000 description 6
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 6
- 231100000359 cholestasis Toxicity 0.000 description 5
- 230000007870 cholestasis Effects 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 238000007654 immersion Methods 0.000 description 5
- 230000000414 obstructive effect Effects 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 208000010157 sclerosing cholangitis Diseases 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 208000016977 Secondary sclerosing cholangitis Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000009093 Dihydrolipoyllysine-residue acetyltransferase Human genes 0.000 description 1
- 108010073112 Dihydrolipoyllysine-residue acetyltransferase Proteins 0.000 description 1
- 241000729176 Fagopyrum dibotrys Species 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000002529 anti-mitochondrial effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000001587 cholestatic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000008938 immune dysregulation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/08—Hepato-biliairy disorders other than hepatitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种原发性胆汁性胆管炎诊断用分子标志物及其应用。本发明将抗人多聚体免疫球蛋白受体抗体作为原发性胆汁性胆管炎诊断用分子标志物,以此来制备诊断用试剂。在PBC AMA‑M2亚型阳性及阴性患者血清中均显著升高,提示在PBC的发病中,血清抗人多聚体免疫球蛋白受体抗体特异性靶向肝内中小胆管上的人多聚体免疫球蛋白受体,从而导致中小胆管的损伤。本发明为PBC发病机制提供了新的解释,此外,通过检测血清抗人多聚体免疫球蛋白受体抗体水平为PBC的特异性诊断提供了新的手段。该方法简单可靠,取材方便,在PBC的诊断中具有极大的应用价值。
Description
技术领域
本发明属于分子生物学技术领域,涉及一种血清抗人多聚体免疫球蛋白受体抗体,具体来说是血清抗人多聚体免疫球蛋白受体抗体作为原发性胆汁性胆管炎诊断用分子标志物及其应用。
背景技术
原发性胆汁性胆管炎(Primary biliary cholangitis,PBC)是一种慢性胆汁淤积性肝病,其特征为中小型肝内胆管自身免疫性破坏,导致进行性胆汁淤积,可缓慢发展为肝硬化和肝衰竭。目前本病全世界每年新诊断病例超过10万例,其主要发生于女性,40岁以上的女性中患病率可能高达0.1%。既往研究表明,遗传和环境因素、免疫失调等多种因素参与了PBC的发病机制,其中线粒体抗原免疫耐受的丧失以及随后出现的涉及体液和细胞免疫的自身免疫反应在PBC发病中发挥至关重要的作用。PBC的自身免疫性特征在于B细胞对线粒体丙酮酸脱氢酶复合物E2亚单位(PDC-E2)的耐受性丧失,导致抗线粒体自身抗体(Antimitochondrial antibodies,AMAs)的产生及自身反应性CD4+与CD8+T激活,而胆管上皮细胞是免疫攻击的目标。然而,一些PBC患者AMA-M2亚型呈阴性,提示PBC并不总是依赖于AMAs介导的特异性免疫反应,且PDC-E2亦在肝细胞中广泛表达,无论是否存在AMAs,为什么自身免疫反应会优先破坏PBC患者中小型肝内胆管目前尚未明确。
Fc受体家族成员人多聚体免疫球蛋白受体是粘膜免疫系统的核心成员,其在黏膜上皮细胞中广泛表达,通常在病毒或细菌感染时被促炎细胞因子诱导上调。人多聚体免疫球蛋白受体可与多聚IgA和多聚IgM特异性结合,通过穿胞转运,将它们从上皮细胞基底侧膜转运到顶膜,并最终分泌到外分泌液中,形成抵抗感染的第一道防线。近年来许多研究表明肝脏人多聚体免疫球蛋白受体高表达是肝纤维化的危险因素,可能与肝炎病毒感染和肝星状细胞转分化有关,人多聚体免疫球蛋白受体还可促进人肝细胞癌(Hepatocellularcarcinoma,HCC)的转移,然而人多聚体免疫球蛋白受体是否参与PBC的发生发展及抗人多聚体免疫球蛋白受体抗体对PBC诊断的价值目前尚未见报道,该指标亦尚未在临床上得到应用。
血清AMAs及其M2亚型是目前临床上PBC重要的辅助诊断指标,然而该指标存在一定的误诊与漏诊比例,故PBC的诊断仍然主要依赖肝组织活检。寻找取材简单可靠的诊断手段与筛选敏感的分子指标是临床上早期确诊PBC亟待解决的重要问题。
发明内容
本发明通过多重免疫组化荧光技术,以胆管细胞标志物细胞角蛋白19(Cytokeratin 19,CK19)为参照,检测AMA-M2阳性PBC、AMA-M2阴性PBC、正常对照(Control,CTR)、梗阻性胆汁淤积(Obstructive cholestasis,OC)、继发性硬化性胆管炎(Secondarysclerosing cholangitis,SSC)及非酒精性脂肪性肝炎(Nonalcoholic steatohepatitis,NASH)患者肝组织中人多聚体免疫球蛋白受体的表达与定位,发现在CTR、OC、SSC及NASH患者中人多聚体免疫球蛋白受体均表达于胆管细胞,但对于PBC患者,无论AMA-M2阳性还是阴性,人多聚体免疫球蛋白受体在肝内中小胆管上的表达均显著降低,基于以上发现,我们猜想在PBC发病过程中,人多聚体免疫球蛋白受体可能为介导免疫损伤的特异性抗原。本发明运用酶联免疫吸附实验(Enzyme linked immunosorbent assay,ELISA)检测CTR、PBC、OC患者的血清,证实了无论AMA-M2阳性还是阴性,PBC患者血清中抗人多聚体免疫球蛋白受体抗体均显著升高,提示抗人多聚体免疫球蛋白受体抗体通过靶向肝内中小胆管上的人多聚体免疫球蛋白受体抗原介导胆管细胞的损伤,故血清抗人多聚体免疫球蛋白受体抗体可作为PBC诊断用分子标志物。目前临床上将检测抗AMA-M2抗体阳性作为诊断PBC的标准之一,易导致抗AMA-M2抗体阴性PBC患者漏诊。故检测抗人多聚体免疫球蛋白受体抗体有助于PBC诊断,特别是AMA-M2阴性PBC患者的诊断。
鉴于现有对患者创伤小且可靠的诊断手段的缺乏,特别是针对抗AMA-M2抗体阴性PBC患者漏诊或误诊的情况,本发明的目的是提供一种PBC诊断用分子标志物及其应用,即血清抗人多聚体免疫球蛋白受体抗体作为PBC诊断用分子标志物。
为了实现上述目的,本发明采用的技术方案是:
一种原发性胆汁性胆管炎诊断用分子标志物,为抗人多聚体免疫球蛋白受体抗体。
本发明还提供一种抗人多聚体免疫球蛋白受体抗体在制备用于诊断PBC患者的试剂中的应用。
进一步,所述PBC患者包括抗AMA-M2抗体阳性PBC患者和抗AMA-M2抗体阴性PBC患者。
进一步,所述诊断PBC患者的试剂用于检测样本中抗人多聚体免疫球蛋白受体抗体的表达水平,所述样本为人血清样本。
进一步,所述诊断PBC患者的试剂为ELISA试剂盒。所述ELISA试剂盒包括微孔酶标板,标准品,样本稀释液,辣根过氧化物酶标记的小鼠抗人多聚体免疫球蛋白单克隆抗体(检测抗体-HRP),20x洗涤缓冲液,底物A,底物B,终止液,封板膜,自封袋。
进一步,所述ELISA试剂盒的检测步骤包括:
从全血标本中提取血清,作为待测样本;
设置标准品孔和样本孔,标准品孔各加不同浓度的标准品50μL,样本孔中加入待测样本50μL;空白孔不加;
除空白孔外,标准品孔和样本孔中每孔加入检测抗体(小鼠抗人多聚体免疫球蛋白单克隆抗体)-HRP 100μL,用封板膜封住反应孔,37℃温育60min;
用洗涤液洗板5次;
每孔加入底物A、B各50μL,37℃避光孵育15min;
每孔加入终止液50μL,15min内,在450nm波长处测定各孔的OD值;
以所测标准品的OD值为横坐标,标准品的浓度值为纵坐标,绘制标准曲线,并得到直线回归方程,将样品的OD值代入方程,计算出样品的浓度。
与现有技术比较本发明的有益效果是:
1.本发明发现抗人多聚体免疫球蛋白受体抗体可作为PBC诊断用的生物标志物。血清AMA-M2是诊断PBC的特异性指标,约90-95%PBC患者AMA-M2阳性;根据AMA-M2是否阳性,PBC分为AMA-M2阳性的PBC与AMA-M2阴性的PBC两种亚型,AMA-M2阴性的PBC临床缺乏特异性诊断标志物,常导致漏诊。本发明发现PBC患者(无论AMA-M2阳性还是阴性)血清中抗人多聚体免疫球蛋白受体抗体水平显著升高,为PBC的诊断,特别是AMA-M2阴性PBC患者的诊断提供了新的标志物。
2.本发明发现的用于诊断PBC的生物标志物抗人多聚体免疫球蛋白受体抗体在临床应用中取材为受试者外周血,取材简单,对受试者创伤小,容易推广。
3.本发明揭示了一种AMA-M2阳性及阴性PBC患者的共同的发病机制,即抗人多聚体免疫球蛋白受体抗体介导的中小型肝内胆管损伤,可以大大减少PBC的漏诊和误诊,特别是AMA-M2阴性PBC患者的漏诊和误诊。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1多重免疫组化荧光染色明确正常对照患者肝脏人多聚体免疫球蛋白受体的表达与定位;
图2多重免疫组化荧光染色明确原发性胆汁性胆管炎AMA-M2阳性患者肝脏人多聚体免疫球蛋白受体的表达与定位;
图3多重免疫组化荧光染色明确原发性胆汁性胆管炎AMA-M2阴性患者肝脏人多聚体免疫球蛋白受体的表达与定位;
图4免疫荧光染色明确梗阻性胆汁淤积患者肝脏人多聚体免疫球蛋白受体的表达与定位;
图5免疫荧光染色明确继发性硬化性胆管炎患者肝脏人多聚体免疫球蛋白受体的表达与定位;
图6免疫荧光染色明确非酒精性脂肪性肝炎肝脏人多聚体免疫球蛋白受体的表达与定位;
图7酶联免疫吸附实验测定正常对照、原发性胆汁性胆管炎、梗阻性胆汁淤积患者血清中抗人多聚体免疫球蛋白受体抗体的水平。
具体实施方式
下面将结合本发明实施例及说明书附图,对本发明中的相关技术进行清楚、完整的描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
在以下实施例中,研究对象的肝组织与血清样本均来自陆军军医大学附属第一医院(西南医院),样本的获取均通过陆军军医大学附属第一医院伦理审批。
实施例1:明确CTR、PBC、OC、SSC及NASH患者肝组织中人多聚体免疫球蛋白受体的表达与定位。
收集西南医院住院部CTR、PBC、OC、SSC及NASH患者手术切除或临床病理诊断后剩余的肝脏组织样本各1例。对肝组织样本进行多聚甲醛固定、脱水透明、浸蜡包埋后进行切片,切片组织厚度为4um。采用多重免疫组化荧光技术检测受试者肝组织中人多聚体免疫球蛋白受体的表达与定位,所用试剂为多重免疫组化荧光试剂盒(Absin,abs50014),具体步骤为:
(1)脱蜡至水:石蜡切片65度烘箱烤片1h;新鲜二甲苯浸片5min,重复3次;梯度乙醇浸片:100%乙醇10min重复2次,95%乙醇10min重复2次;灭菌水洗片5min,重复两次。
(2)抗原修复:Tris-EDTA微波修复高火2min,中高火13min,晾30min左右至室温;灭菌水浸洗3min;TBST浸洗3min。
(3)内源性过氧化物酶阻断:滴加内源性过氧化物酶阻断剂(中杉金桥,SP-9000),室温孵育10min;TBST浸洗3min重复2次。
(4)封闭:8%山羊血清(Absin,abs933)室温孵育10min。
(5)一抗孵育:抗细胞角蛋白19抗体(Abcam,ab52625)用8%山羊血清按1:500稀释,室温保湿孵育1h。TBST浸洗玻片3min,重复2次。
(6)一抗孵育期间将二抗工作液平衡至室温。
(7)二抗孵育:滴加二抗工作液溶液,浸没样本区域,室温保湿孵育10min。后用TBST浸洗玻片3min,重复2次。
(8)荧光染色放大信号:用信号放大液按1:100稀释HRP 520染料,用移液器在玻片上滴加染料浸没样本区域,室温保湿孵育10min。后用TBST浸洗玻片,室温浸片3min重复3次。
(9)抗原修复:Tris-EDTA微波修复高火2min,中高火13min,晾30min左右至室温;灭菌水浸洗3min;TBST浸洗3min。
(10)封闭:8%山羊血清室温孵育10min。
(11)一抗孵育:抗人多聚体免疫球蛋白受体抗体(Proteintech,22024-1-AP)用8%山羊血清按1:500稀释,室温保湿孵育1h;用TBST浸洗玻片3min,重复2次。一抗孵育期间将二抗工作液平衡至室温。
(12)二抗孵育:滴加二抗工作液溶液,浸没样本区域,室温保湿孵育10min;后用TBST浸洗玻片3min重复2次。
(13)荧光染色放大信号:用信号放大液按1:100稀释HRP 570染料,用移液器在玻片上滴加染料浸没样本区域。室温保湿孵育10min。TBST浸洗玻片,室温浸片3min重复3次
(14)染核及封片:滴加1×DAPI(用ddH2O稀释按1:100)工作液到样品上,室温孵育5min。用TBST浸洗玻片3次,每次2min。滴加抗荧光淬灭封片剂,用盖玻片封片。对染色后的组织片在共聚焦显微镜下观察并分析。
本发明通过以上实验步骤证明,与正常对照(图1)相比,原发性胆汁性胆管炎患者无论AMA-M2阳性(图2)还是阴性(图3),人多聚体免疫球蛋白受体在肝内中小胆管上的表达均显著降低,而梗阻性胆汁淤积(图4)、继发性硬化性胆管炎(图4)及非酒精性脂肪性肝病(图6)患者与正常对照相似,人多聚体免疫球蛋白受体均表达于胆管上皮细胞。
实施例2:明确CTR、PBC、OC患者血清抗人多聚体免疫球蛋白受体抗体的表达。
收集西南医院住院部12例CTR、17例PBC、15例OC患者的外周血标本,采用酶联免疫吸附试验(ELISA)检测受试者血清中抗人多聚体免疫球蛋白受体抗体的表达,所用试剂为人多聚体免疫球蛋白受体抗体ELISA试剂盒(仑昌硕生物,100712),具体步骤为:
(1)取血清:
将收集于血清分离管的全血标本在室温放置2小时或4℃过夜,然后1000×g离心20分钟,取上清即可,或将上清置于-20℃或-80℃保存,避免反复冻融。
(2)试剂及器材准备:
微孔酶标板,标准品,样本稀释液,检测抗体-HRP,20×洗涤缓冲液,底物A,底物B,终止液,封板膜,酶标仪(450nm),高精度加样器及枪头:0.5-10uL、2-20uL、20-200uL、200-1000uL,37℃恒温箱,蒸馏水或去离子水。
20×洗涤缓冲液的稀释:蒸馏水按1:20稀释,即1份20×洗涤缓冲液加19份蒸馏水。
(3)操作步骤
从室温平衡20min后的铝箔袋中取出所需板条,剩余板条用自封袋密封放回4℃。
设置标准品孔和样本孔,标准品孔各加不同浓度的标准品50μL,样本孔中加入待测样本50μL;空白孔不加。
除空白孔外,标准品孔和样本孔中每孔加入辣根过氧化物酶(HRP)标记的检测抗体(小鼠抗人多聚体免疫球蛋白单克隆抗体)-HRP 100μL,用封板膜封住反应孔,37℃水浴锅或恒温箱温育60min。
弃去液体,吸水纸上拍干,每孔加满洗涤液(350μL),静置1min,甩去洗涤液,吸水纸上拍干,如此重复洗板5次(也可用洗板机洗板)。
每孔加入底物A、B各50μL,37℃避光孵育15min。
每孔加入终止液50μL,15min内,在450nm波长处测定各孔的OD值。
(4)结果计算
以所测标准品的OD值为横坐标,标准品的浓度值为纵坐标,绘制标准曲线,并得到直线回归方程,将样品的OD值代入方程,计算出样品的浓度。
本发明通过以上实验步骤证明,与正常对照和梗阻性胆汁淤积患者相比,无论AMA-M2阳性还是阴性,原发性胆汁性胆管炎患者血清中抗人多聚体免疫球蛋白受体抗体均显著升高(图7),提示抗人多聚体免疫球蛋白受体抗体通过靶向肝内中小胆管上的人多聚体免疫球蛋白受体抗原介导胆管细胞的损伤,故血清抗人多聚体免疫球蛋白受体抗体可作为原发性胆汁性胆管炎诊断用分子标志物。
以上详细描述了本发明的较佳具体实施例。应当理解,本领域的普通技术人员无需创造性劳动就可以根据本发明的构思做出诸多修改变化。凡在本发明的精神和原则之内所作的任何修改、等同替换、改进等,均包含在本发明的保护范围内。
Claims (8)
1.一种原发性胆汁性胆管炎诊断用分子标志物,其特征在于:所述标志物为抗人多聚体免疫球蛋白受体抗体。
2.权利要求1所述抗人多聚体免疫球蛋白受体抗体在制备用于诊断PBC患者的试剂中的应用。
3.根据权利要求2所述应用,其特征在于:所述PBC患者包括抗AMA-M2抗体阳性PBC患者和抗AMA-M2抗体阴性PBC患者。
4.根据权利要求2或3所述应用,其特征在于:所述诊断PBC患者的试剂用于检测样本中抗人多聚体免疫球蛋白受体抗体的表达水平。
5.根据权利要求4所述应用,其特征在于:所述样本为人血清样本。
6.根据权利要求4所述应用,其特征在于:所述诊断PBC患者的试剂为ELISA试剂盒。
7.根据权利要求6所述应用,其特征在于:所述ELISA试剂盒包括微孔酶标板,标准品,样本稀释液,辣根过氧化物酶标记的小鼠抗人多聚体免疫球蛋白单克隆抗体(检测抗体-HRP),20x洗涤缓冲液,底物A,底物B,终止液,封板膜,自封袋。
8.根据权利要求7所述应用,其特征在于:所述ELISA试剂盒的检测步骤包括:
从全血标本中提取血清,作为待测样本;
设置标准品孔和样本孔,标准品孔各加不同浓度的标准品50μL,样本孔中加入待测样本50μL;空白孔不加;
除空白孔外,标准品孔和样本孔中每孔加入辣根过氧化物酶标记的检测抗体(小鼠抗人多聚体免疫球蛋白单克隆抗体)100μL,用封板膜封住反应孔,37℃温育60min;
用洗涤液洗板5次;
每孔加入底物A、B各50μL,37℃避光孵育15min;
每孔加入终止液50μL,15min内,在450nm波长处测定各孔的OD值;
以所测标准品的OD值为横坐标,标准品的浓度值为纵坐标,绘制标准曲线,并得到直线回归方程,将样品的OD值代入方程,计算出样品的浓度。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111375805.0A CN114088939A (zh) | 2021-11-19 | 2021-11-19 | 一种原发性胆汁性胆管炎诊断用分子标志物及其应用 |
EP22893985.6A EP4379381A1 (en) | 2021-11-19 | 2022-04-20 | Molecular marker for diagnosis of primary biliary cholangitis and use thereof |
US18/281,804 US20240159748A1 (en) | 2021-11-19 | 2022-04-20 | Molecular marker for diagnosing primary biliary cholangitis and method for detecting same |
PCT/CN2022/087926 WO2023087616A1 (zh) | 2021-11-19 | 2022-04-20 | 一种原发性胆汁性胆管炎诊断用分子标志物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111375805.0A CN114088939A (zh) | 2021-11-19 | 2021-11-19 | 一种原发性胆汁性胆管炎诊断用分子标志物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114088939A true CN114088939A (zh) | 2022-02-25 |
Family
ID=80302268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111375805.0A Pending CN114088939A (zh) | 2021-11-19 | 2021-11-19 | 一种原发性胆汁性胆管炎诊断用分子标志物及其应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240159748A1 (zh) |
EP (1) | EP4379381A1 (zh) |
CN (1) | CN114088939A (zh) |
WO (1) | WO2023087616A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023087616A1 (zh) * | 2021-11-19 | 2023-05-25 | 中国人民解放军陆军军医大学第一附属医院 | 一种原发性胆汁性胆管炎诊断用分子标志物及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118010601A (zh) * | 2024-04-07 | 2024-05-10 | 中国医学科学院北京协和医院 | 一种用于诊断原发性胆汁性胆管炎的系统 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1221428A (zh) * | 1996-06-04 | 1999-06-30 | 加利福尼亚大学董事会 | Pigr生物大分子特征性高级结构和相关配体的细胞内化作用 |
US20050032034A1 (en) * | 1999-10-15 | 2005-02-10 | Dodds W. Jean | Animal health diagnostic system |
CN102841200A (zh) * | 2011-06-24 | 2012-12-26 | 中国科学院上海药物研究所 | pIgR作为肿瘤早期复发和/或转移的分子标志物和抗肿瘤转移的药物干预靶点的用途 |
WO2014071455A1 (en) * | 2012-11-08 | 2014-05-15 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Diagnostic, prognostic, therapeutic and screening protocols with respect to infectious mycobacterium |
CN109085344A (zh) * | 2018-09-18 | 2018-12-25 | 温州医科大学附属第医院 | 利用血清外泌体pIgR作为原发性胆汁性胆管炎诊断及疗效预测的标志物的试剂盒及应用 |
WO2021146776A1 (en) * | 2020-01-24 | 2021-07-29 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Detecting gut barrier dysfunction and/or cirrhosis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8705137D0 (sv) * | 1987-12-22 | 1987-12-22 | Pharmacia Ab | Diagnostic method for primary biliary cirrhosis and antibodies suitable to be used in certain versions of the method |
KR100545064B1 (ko) * | 2003-05-26 | 2006-01-24 | 김현기 | 인간 원암단백질에 특이적인 항체를 포함하는 간경변증진단 키트 |
WO2011026036A1 (en) * | 2009-08-28 | 2011-03-03 | Inova Diagnostics, Inc. | Detecting circulating cartilage oligomeric matrix protein in liver cirrhosis |
CN102435733B (zh) * | 2011-08-12 | 2014-03-05 | 徐斌 | 一种AFP-IgM检测试剂盒及检测方法 |
CN103044548A (zh) * | 2011-12-23 | 2013-04-17 | 北京大学人民医院 | 一种原发性胆汁性肝硬化的特异性自身抗体及应用 |
CN106153893B (zh) * | 2016-06-14 | 2018-01-16 | 浙江大学 | 唾液抗线粒体抗体m2型的酶联免疫检测试剂盒 |
CN114088939A (zh) * | 2021-11-19 | 2022-02-25 | 中国人民解放军陆军军医大学第一附属医院 | 一种原发性胆汁性胆管炎诊断用分子标志物及其应用 |
-
2021
- 2021-11-19 CN CN202111375805.0A patent/CN114088939A/zh active Pending
-
2022
- 2022-04-20 EP EP22893985.6A patent/EP4379381A1/en active Pending
- 2022-04-20 US US18/281,804 patent/US20240159748A1/en active Pending
- 2022-04-20 WO PCT/CN2022/087926 patent/WO2023087616A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1221428A (zh) * | 1996-06-04 | 1999-06-30 | 加利福尼亚大学董事会 | Pigr生物大分子特征性高级结构和相关配体的细胞内化作用 |
US20050032034A1 (en) * | 1999-10-15 | 2005-02-10 | Dodds W. Jean | Animal health diagnostic system |
CN102841200A (zh) * | 2011-06-24 | 2012-12-26 | 中国科学院上海药物研究所 | pIgR作为肿瘤早期复发和/或转移的分子标志物和抗肿瘤转移的药物干预靶点的用途 |
WO2014071455A1 (en) * | 2012-11-08 | 2014-05-15 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Diagnostic, prognostic, therapeutic and screening protocols with respect to infectious mycobacterium |
CN109085344A (zh) * | 2018-09-18 | 2018-12-25 | 温州医科大学附属第医院 | 利用血清外泌体pIgR作为原发性胆汁性胆管炎诊断及疗效预测的标志物的试剂盒及应用 |
WO2021146776A1 (en) * | 2020-01-24 | 2021-07-29 | Macfarlane Burnet Institute For Medical Research And Public Health Limited | Detecting gut barrier dysfunction and/or cirrhosis |
Non-Patent Citations (1)
Title |
---|
SANHITA GUPTA 等: "Antibodies to the Polymeric Immunoglobulin Receptor with Different Binding and Trafficking Patterns", 《AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY》, vol. 33, pages 363 - 370 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023087616A1 (zh) * | 2021-11-19 | 2023-05-25 | 中国人民解放军陆军军医大学第一附属医院 | 一种原发性胆汁性胆管炎诊断用分子标志物及其应用 |
Also Published As
Publication number | Publication date |
---|---|
US20240159748A1 (en) | 2024-05-16 |
WO2023087616A1 (zh) | 2023-05-25 |
EP4379381A1 (en) | 2024-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114088939A (zh) | 一种原发性胆汁性胆管炎诊断用分子标志物及其应用 | |
Sutummaporn et al. | Association of feline morbillivirus infection with defined pathological changes in cat kidney tissues | |
CN102066931A (zh) | 人乳头状瘤病毒早期及晚期感染之免疫分析试验 | |
Cobbs et al. | Methods for the detection of cytomegalovirus in glioblastoma cells and tissues | |
Luo et al. | Leukemia inhibitory factor receptor is a novel immunomarker in distinction of well-differentiated HCC from dysplastic nodules | |
Meehan et al. | Nephron segment localization of polyoma virus large T antigen in renal allografts | |
CN110531077B (zh) | 间皮素免疫组化检测试剂盒 | |
CN103044548A (zh) | 一种原发性胆汁性肝硬化的特异性自身抗体及应用 | |
CN111187349A (zh) | 单克隆抗体的制备方法 | |
CN102944681A (zh) | 非小细胞肺癌胸水肿瘤标志物的应用 | |
CN112430583B (zh) | 一种抗hpv e7的单克隆抗体及其细胞株和应用 | |
CN114085909A (zh) | Top1作为宫颈癌标志物和/或治疗靶点的应用 | |
CN112458061B (zh) | 一种抗hpv e6的单克隆抗体及其细胞株和应用 | |
CN107643283B (zh) | 干扰素诱导T细胞α趋化因子在制备原发性胆汁性胆管炎诊断试剂或试剂盒中的应用 | |
CN105699649B (zh) | 用于术前检测肝癌微血管侵犯的血清标记物 | |
CN110542755A (zh) | 一种利用免疫标记法检测塞尼卡谷病毒的试剂盒及其检测方法 | |
Rose et al. | Immunohistochemical analysis of urothelial carcinoma tissues for proliferation and differentiation markers | |
CN114214405B (zh) | 一种用于肝癌转移预测的试剂、试剂盒及方法 | |
CN210893865U (zh) | 一种免疫组化检测用载玻片 | |
Pantin-Jackwood | Immunohistochemical staining for the detection of the avian influenza virus in tissues | |
US20180299447A1 (en) | Cervical cancer testing method and test reagent used therefor | |
Vaz-de-Lima et al. | Performance of indirect immunofluorescence assay, immunochromatography assay and reverse transcription-polymerase chain reaction for detecting human respiratory syncytial virus in nasopharyngeal aspirate samples | |
Mandarano et al. | On the need of a suitable Immunohistochemical test for demonstration of SARS-CoV-2 on formalin-fixed and paraffin-embedded tissues | |
CN106834457A (zh) | 一种结核分枝杆菌感染程度的定量测定方法 | |
CN110095605B (zh) | 一种肺癌的筛查试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |